Methadone in Post-Herpetic Neuralgia Pain (NPH)
Neuropathic pain is a common condition and affecting 40 to 70% of the general population. Post-herpetic neuralgia is a condition almost complex and requires a multi modal treatment. Aim: This is a pilot proof-of-principle study designed to evaluate the use of low-dose methadone in post-herpetic neuralgia patients who remained refractory after first and second line treatment for post-herpetic neuralgia (PHN) and had indication for the association of an opioid agent to their current drug regimen.
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Outcomes Assessor)
Primary Purpose: Treatment
|Official Title:||Methadone in Post-Herpetic Neuralgia Pain|
- Change in baseline Pain [ Time Frame: baseline (visit inclusion) and three moths latter ] [ Designated as safety issue: No ]Assessing by verbal analog scale (VAS)
|Study Start Date:||January 1998|
|Study Completion Date:||March 2013|
|Primary Completion Date:||February 2013 (Final data collection date for primary outcome measure)|
in this arm patients will take methadone 5mg.
patients with post-herpetic neuralgia take methadone or placebo to treat pain symptoms.
in this arm patients will take placebo pills.
patients with post-herpetic neuralgia take placebo to treat the pain symptoms.